Arsenic Power (Arsenic Trioxide Vials) 10mg/10ml

Arsenic trioxide 10mg/10ml vials are prescribed for certain blood cancers under medical supervision. This chemotherapy agent targets malignant cells while sparing healthy tissue. Always consult a healthcare professional before use. Short-term storage guidance may apply per label instructions.

Strength

10mg/10ml

Manufacturer / TM Owner

GNH India Pharmaceuticals Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Arsenic trioxide is used to treat acute promyelocytic leukemia (APL) and other hematologic malignancies when standard therapies are ineffective. It works by promoting cancer cell differentiation and inducing apoptosis. Patients often inquire about what arsenic trioxide is used for in oncology settings. This formulation is administered intravenously in clinical environments.

Side Effects

Common effects include nausea, fatigue, and electrolyte imbalances during treatment cycles. Some patients report headaches or skin reactions at injection sites. These responses vary by individual and are monitored by healthcare providers.

Precautions & Warnings

Handle vials with care to avoid contamination or accidental exposure. Store in a secure, temperature-controlled area away from direct light. Only trained personnel should prepare and administer this medication. Follow universal precautions for cytotoxic drugs.

Avoid Interactions

Caution is advised when combining with other cardiotoxic or QT-prolonging agents. Herbal supplements and grapefruit products may alter metabolism. Always disclose all medications to your healthcare team before starting arsenic trioxide.

Frequently Asked Questions

Arsenic trioxide is primarily used to treat acute promyelocytic leukemia (APL) and certain other blood cancers when standard therapies are not effective.

This medication is administered intravenously by healthcare professionals in a clinical setting, following specific dosing protocols.

Common side effects may include nausea, fatigue, electrolyte imbalances, headaches, or skin reactions at injection sites.

Arsenic trioxide is a prescription medication and should only be obtained through licensed healthcare providers or pharmacies.

Arsenic trioxide is not recommended during pregnancy due to potential risks; discuss alternatives with your doctor.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.